Crystal Structure, Conformational Fixation and Entry-related Interactions of Mature Ligand-free HIV-1 Env

As the sole viral antigen on the HIV-1-virion surface, trimeric Env is a focus of vaccine efforts. Here we present the structure of the ligand-free HIV-1-Env trimer, fix its conformation and determine its receptor interactions. Epitope analyses revealed trimeric ligand-free Env to be structurally compatible with broadly neutralizing antibodies but not poorly neutralizing ones. We coupled these compatibility considerations with binding antigenicity to engineer conformationally fixed Envs, including a 201C 433C (DS) variant specifically recognized by broadly neutralizing antibodies. DS-Env retained nanomolar affinity for the CD4 receptor, with which it formed an asymmetric intermediate: a closed trimer bound by a single CD4 without the typical antigenic hallmarks of CD4 induction. Antigenicity-guided structural design can thus be used both to delineate mechanism and to fix conformation, with DS-Env trimers in virus-like-particle and soluble formats providing a new generation of vaccine antigens.

Citing Articles

The membrane-proximal external region of human immunodeficiency virus (HIV-1) envelope glycoprotein trimers in A18-lipid nanodiscs.

Qi Y, Zhang S, Wang K, Ding H, Zhang Z, Anang S Commun Biol. 2025; 8(1):442.

PMID: 40089599 DOI: 10.1038/s42003-025-07852-z.

Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview.

Boomgarden A, Upadhyay C Vaccines (Basel). 2025; 13(2).

PMID: 40006695 PMC: 11860913. DOI: 10.3390/vaccines13020148.

Structural development of the HIV-1 apex-directed PGT145-PGDM1400 antibody lineage.

Mason R, Zhang B, Morano N, Shen C, McKee K, Heimann A Cell Rep. 2025; 44(1):115223.

PMID: 39826122 PMC: 11883830. DOI: 10.1016/j.celrep.2024.115223.

HIV-1-envelope trimer transitions from prefusion-closed to CD4-bound-open conformations through an occluded-intermediate state.

Lee M, Lu M, Zhang B, Zhou T, Katte R, Han Y Comput Struct Biotechnol J. 2024; 23:4192-4204.

PMID: 39640534 PMC: 11617889. DOI: 10.1016/j.csbj.2024.11.020.

Neutralizing antibodies elicited in macaques recognize V3 residues on altered conformations of HIV-1 Env trimer.

DeLaitsch A, Keeffe J, Gristick H, Lee J, Ding W, Liu W NPJ Vaccines. 2024; 9(1):240.

PMID: 39638818 PMC: 11621127. DOI: 10.1038/s41541-024-01038-0.

References

Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N . Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996; 70(2):1100-8. PMC: 189917. DOI: 10.1128/JVI.70.2.1100-1108.1996. View

Calarese D, Scanlan C, Zwick M, Deechongkit S, Mimura Y, Kunert R . Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science. 2003; 300(5628):2065-71. DOI: 10.1126/science.1083182. View

Tang G, Peng L, Baldwin P, Mann D, Jiang W, Rees I . EMAN2: an extensible image processing suite for electron microscopy. J Struct Biol. 2006; 157(1):38-46. DOI: 10.1016/j.jsb.2006.05.009. View

Weiss R, Clapham P, Dalgleish A, Carne C, Weller I, Tedder R . Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature. 1985; 316(6023):69-72. DOI: 10.1038/316069a0. View

Bartesaghi A, Merk A, Borgnia M, Milne J, Subramaniam S . Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat Struct Mol Biol. 2013; 20(12):1352-7. PMC: 3917492. DOI: 10.1038/nsmb.2711. View

Mbah H, Burda S, Gorny M, Williams C, Revesz K, Zolla-Pazner S . Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades. J Virol. 2001; 75(16):7785-8. PMC: 115019. DOI: 10.1128/JVI.75.16.7785-7788.2001. View

McLellan J, Yang Y, Graham B, Kwong P . Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011; 85(15):7788-96. PMC: 3147929. DOI: 10.1128/JVI.00555-11. View

Arthos J, Cicala C, Steenbeke T, Chun T, Dela Cruz C, Hanback D . Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. J Biol Chem. 2002; 277(13):11456-64. DOI: 10.1074/jbc.M111191200. View

Burton D, Pyati J, Koduri R, Sharp S, Thornton G, Parren P . Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 1994; 266(5187):1024-7. DOI: 10.1126/science.7973652. View

10.

Huang J, Kang B, Pancera M, Lee J, Tong T, Feng Y . Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature. 2014; 515(7525):138-42. PMC: 4224615. DOI: 10.1038/nature13601. View

11.

Gorny M, Sampson J, Li H, Jiang X, Totrov M, Wang X . Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure. PLoS One. 2011; 6(12):e27780. PMC: 3229485. DOI: 10.1371/journal.pone.0027780. View

12.

Swanson K, Settembre E, Shaw C, Dey A, Rappuoli R, Mandl C . Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A. 2011; 108(23):9619-24. PMC: 3111287. DOI: 10.1073/pnas.1106536108. View

13.

Dreyfus C, Laursen N, Kwaks T, Zuijdgeest D, Khayat R, Ekiert D . Highly conserved protective epitopes on influenza B viruses. Science. 2012; 337(6100):1343-8. PMC: 3538841. DOI: 10.1126/science.1222908. View

14.

Wei X, Decker J, Liu H, Zhang Z, Arani R, Michael Kilby J . Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002; 46(6):1896-905. PMC: 127242. DOI: 10.1128/AAC.46.6.1896-1905.2002. View

15.

Kwong P, Doyle M, Casper D, Cicala C, Leavitt S, Majeed S . HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 2002; 420(6916):678-82. DOI: 10.1038/nature01188. View

16.

Sanner M, Olson A, Spehner J . Reduced surface: an efficient way to compute molecular surfaces. Biopolymers. 1996; 38(3):305-20. DOI: 10.1002/(SICI)1097-0282(199603)38:3%3C305::AID-BIP4%3E3.0.CO;2-Y. View

17.

Pancera M, Lebowitz J, Schon A, Zhu P, Freire E, Kwong P . Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis. J Virol. 2005; 79(15):9954-69. PMC: 1181572. DOI: 10.1128/JVI.79.15.9954-9969.2005. View

18.

Scheid J, Mouquet H, Feldhahn N, Seaman M, Velinzon K, Pietzsch J . Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009; 458(7238):636-40. DOI: 10.1038/nature07930. View

19.

Nicholls A, Sharp K, Honig B . Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins. 1991; 11(4):281-96. DOI: 10.1002/prot.340110407. View

20.

Sarzotti-Kelsoe M, Bailer R, Turk E, Lin C, Bilska M, Greene K . Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods. 2013; 409:131-46. PMC: 4040342. DOI: 10.1016/j.jim.2013.11.022. View